search

Active clinical trials for "Short Bowel Syndrome"

Results 91-100 of 122

Sham Feeding Post-operative Infants

Newborn MorbidityOral Aversion3 more

The purpose of this pilot study is to evaluate a feeding technique, sham feeding, to promote adequate oral skills in order to prevent oral aversion and/or poor oral skills due to the delay in oral feeds for surgical reasons. Sham feeding is intended for infants who are expected to have a prolonged course without normal enteral feeding by mouth.

Completed4 enrollment criteria

Nonthyroidal Illness Syndrome in SBS

Nonthyroidal Illness SyndromeShort Bowel Syndrome

Nonthyroidal illness syndrome (NTIS) is prevalent in critical illness; it is associated with poor outcomes. However, few studies have focused on the relationship between NTIS and short bowel syndrome (SBS). The aim of this study was to investigate the incidence, etiology, and prognosis of NTIS and its correlation in clinical variables in adult patients with SBS.

Completed9 enrollment criteria

A Study to Monitor the Use of an Amino Acid-Based Infant Formula

Cow's Milk Protein AllergyEosinophilic Gastrointestinal Disorders3 more

To assess the frequency and nature of adverse events in infants fed a free amino acid based infant formula.

Completed5 enrollment criteria

A Study of Teduglutide (Revestive®) in Children, Teenagers and Adults With Short Bowel Disease

Short Bowel Syndrome

The main aims of the study are to assess the safety profile of Teduglutide (Revestive®) in people with Short Bowel Disease as well as how well people respond to the treatment with Teduglutide (Revestive®). This study is about collecting data only; participants receive Teduglutide (Revestive®) by their doctors according to the clinical practice but not as part of this study. Only standard care information available in the participant's medical records will be reviewed and collected for this study. Participants do not need to visit their doctor in addition to their normal visits.

Completed4 enrollment criteria

A Study With Teduglutide (Revestive®) in Adults With Short Bowl Syndrome

Short Bowel Syndrome

The main aims of the study are to assess the safety profile of teduglutide (Revestive®) as well as how many people with Short Bowl Syndrome experience a reduction of parenteral support when treated with teduglutide (Revestive®). This study is about collecting existing data only; participants will not receive teduglutide (Revestive®) as part of this study. No new information will be collected during this study. Only data already available in the hospital records will be reviewed and collected for this study. Participants do not need to visit their doctor in addition to their normal visits.

Completed5 enrollment criteria

Home Parenteral Nutrition (HPN) Families' Mobile Distance Connections to Care Research

Short Bowel SyndromeMalabsorption1 more

The purpose of this study is to test Mobile Technologies in Assisting Patients & Family Caregivers in Healthy Living and complex home care by connecting to information and professionals from a distance.

Completed10 enrollment criteria

Comparison of Different Oral Rehydration Solutions

Short Bowel Syndrome

Compliance is the biggest challenge in patients with Short Bowel Syndrome (SBS) on Home Parenteral Nutrition. These patients need to hydrate themselves to meet the excess fluid loss due to their anatomy. Oral Rehydration Solution (ORS) is prescribed to all these patients. The investigators believe that taste of the standard ORS is the biggest reason why these patients are not complaint. The new ORS in the market has been prepared with this in mind. The investigators want to study if this new ORS will improve the compliance in this patient cohort.

Completed6 enrollment criteria

Citrulline: A Plasmatic Marker to Assess and Monitor Small Bowel Crohn's Disease Patients

Crohn's DiseaseShort Bowel Syndrome2 more

Citrulline is an amino acid produced in the intestine and in the liver, but the liver does not contribute significantly to circulating citrulline concentrations. The intestine is thus the only organ that normally releases significant amounts of citrulline into the blood. The investigators have designed a study looking at the value of measuring plasma citrulline concentration in patients with Crohn's disease and short bowel or normal intestinal length. Measuring the plasma citrulline concentration in short bowel patients may help to distinguish between patients who need permanent parenteral feeding from patients with just transient intestinal dysfunction. It may also help the investigators in understanding the small bowel intestinal length remaining and the absorptive integrity. In patients with normal intestinal length and Crohn's disease, it may be a reliable marker of small bowel damage and could be applied to establish therapeutic improvements. It has been demonstrated to strongly correlate (inversely) with severity on intestinal biopsies. The investigators hypothesise that the plasma citrulline concentration is a marker for small bowel absorptive integrity and an appropriate surrogate for functional length of the small intestine. Controlled data do not yet exist to establish the place of plasma citrulline in the assessment of small bowel function in man.

Completed15 enrollment criteria

Plasma Determination of Glucagon-like Peptide 2 as a Predictor of Recovery in Adults With Acute...

Short Bowel Syndrome

The purpose of this study is to investigate the theory that the plasma level of Glucagon like peptide 2 (GLP-2) in patients with intestinal failure can predict their clinical recovery.

Completed8 enrollment criteria

Trial of 70% Ethanol Versus Heparin to Reduce the Rate of Central Line Infections in Children With...

Catheter Related InfectionsShort Bowel Syndrome

This study is designed to determine if the use of 70% ethanol lock solution in central lines decreases the rate of central line infections in children with short bowel syndrome. While ethanol locks have been used safely in children, there has been no published research to date that clearly shows it is of definite benefit in this group of patients.

Withdrawn9 enrollment criteria
1...91011...13

Need Help? Contact our team!


We'll reach out to this number within 24 hrs